

Electronic Synoptic Surgical Reporting –Implementation and Benefits Evaluation

Shaheena Mukhi
Canadian Partnership Against Cancer
Manager, Standards, Diagnosis and Clinical Care


Chad Leaver
Canada Health Infoway
Clinical Adoption, Benefits Realization Leader
May, 2015



Presentation Overview

- Background
- Pan-Canadian scope
- Method
- Key findings
- Clinical value
- Opportunities
- Future direction

Accelerating Synoptic Reporting in Canada



Manage People New Triage Staging Assign MD Save Copy To Word Cursor

- Additional Dimension (cm)
 - Reason Size Cannot
- Microscopic
 - Histologic Type
 - Noninvasive carcinoma
 - Invasive carcinoma
 - Size of invasive component (microscopic measurement)
 - Greatest Dimension (cm)
 - Second Dimension (cm)
 - Third Dimension (cm)
 - Reason Size Cannot Be Determined
 - Histologic Grade
 - Nottingham System (Elston-Ellis/Scarff-Bloom-Richardson)

CAP Checklist, modified to requirements of your institution.

Report Entries	Hint	Info	Info Content	Properties
Invasive carcinoma:				Inva
Size of invasive component (microscopic measurement)				
Greatest Dimension (cm):				0.8
Histologic Grade :				
Nottingham System (Elston-Ellis/Scarff-Bloom-Richardson)				
Tubule formation:				Mo
Nuclear Pleomorphism:				Sm
Mitotic count:				10
Total Nottingham Score:				Gra
Margin Involvement				
Margins (invasive):				Inva

Synoptic Reporting

e.g. Structured Surgical Report

- Electronic capture of clinical information/documentation in a **standardized, structured** way
- Incorporates evidence-informed best practices and **clinically validated** data elements to facilitate clinical decision making to improve patient outcomes
- Enables clinicians to gain timely access to **concisely-reported and clinically-relevant** information

©Canada Health Infoway 2015

Pre



Post



Report Entries	Info Content	Properties
Invasive carcinoma	Size of invasive component (microscopic measurement)	
	Greatest Dimension (cm)	0.8
	Histologic Grade	
	Nottingham System (Elston-Ellis/Scarff-Bloom-Richardson)	
	Tubule formation	Moderate
	Nuclear Pleomorphism	Small regular nuclei (score = 1)
	Mitotic count	10 to 20 mitoses per 10 HPF [25x objective] (score = 2)
	Total Nottingham Score	Grade 1-3-5 points
Margins involvement	Margins (invasive)	Invasive tumor extends to margin(s)

Synoptic Reporting - Infoway Projects (2014-2015)

Infoway invested with partners in synoptic reporting initiatives to establish pan-Canadian templates and demonstrate emerging benefits from early adoption



- Screening
- Surgery
- Care Transition
- Pathology

Background

- Surgical information narrated, traditionally
- Synoptic surgical reporting (SSR) captures structured, evidenced-based operative data electronically
- Piloted in 2008, in 5 provinces (4 cancer surgery disease site)
- Pan-Canadian implementation in 4 provinces for eight cancer surgery sites
 - Breast, colon, rectal, ovarian, endometrial, thyroid, lung and prostate—60% of incident cancer cases in Canada
 - Advance the development and implementation of pan-Canadian standards for surgical cancer reporting and promote adoption
 - Facilitate clinical decision-making and improve outcomes

Pan-Canadian Scope –SSR

Implement and evaluate benefits

With funding from Infoway and through engagement with surgical clinical leaders and provincial partners:

- Integrated clinical guidelines and content standards into the development of data collection tools
- Alberta, Manitoba, Ontario and Nova Scotia used electronic surgical synoptic reporting
- Identified and measured indicators to support outcomes reporting at pan-Canadian and provincial levels
 - Areas: quality, access and productivity

Method

- The Benefits Evaluation Framework, by Infoway, guided the data collection and analysis
- Data collection: October 2013 – April 2014
 - Clinicians collected surgical care data for 8 disease sites electronically
 - SNOMED CT International (v.2014) supported data extraction to analyze and measure clinical outcomes indicators
- Study design: mixed methods
 - Quantitative—descriptive statistics
 - Surgical care synoptic reporting—data on process and outcomes of cancer operations
 - Survey data: clinician satisfaction levels
 - Qualitative
 - Interviews and focus groups

Key Findings

- Transitioning from narrative to synoptic surgical reporting: surgeons' satisfaction levels

Indicator	Data accuracy	Data relevance	Data availability	Data timeliness	Data comprehensive	Ease of use	Improves patient care	Expedites clinical decision
Satisfaction scores (%)	92%	89%	86%	71%	68%	86%	70%	52%*

Indicator	Security	Coordinates care with health care team	Fits work flow	Improves patient safety	Discharge summary efficient
Satisfaction scores (%)	89%	78%	75%	52%*	71%

* Score 52% reflects respondents' belief that their current practice, prior to synoptic reporting, was already at an acceptable level

Key Findings

Discrete, consistent and comprehensive surgical operative data:

- 2941 synoptic surgical reports and 729 discharge summaries

Disease site	Breast	Colon	Rectal	Ovarian	Endometrial	Thyroid	Lung	Prostate
Discrete data collection	1702	168	123	185	149	392	104	118

- **Impact to clinical care and patient care**

- Synoptic surgical reporting improves data timeliness and availability (82% - 100%), enables clinical investigations and informs treatment plans for 60% of incident cancer cases in Canada

- Turnaround times for discharge summaries to reach patient charts

Median	Baseline (narrative)	Electronic Synoptic (discrete data)
1.0 days	15% of discharge summaries	74.5% discharge summaries

Clinical Use and Value of SSR data

Breast Cancer

The proportion of patients with stage I or II breast cancer who underwent sentinel lymph node (SLN) biopsy

Indicator: Percent of stage I or II breast cancers undergoing sentinel lymph node (SLN) biopsy

Provinces	Total number of patients surgically treated for clinical stage 1 or 2 breast cancer	Sentinel lymph node biopsy done on patients who were surgically treated for clinical stage 1 or 2 breast cancer	Percent (%)
Provinces Combined	527	378	71.1
AB	406	278	68.5
MB	28	24	85.7
ON	14	9	64.3
NS	79	67	84.8

Clinical Use and Value of SSR Data

Prostate Cancer

The proportion of patients with complete removal of seminal vesicles, associated with improved outcomes

Indicator: Percent Complete removal of seminal vesicles

Provinces	Total patients who underwent surgery	Number of patients with complete seminal vesicle dissection	Percent (%)
Provinces Combined (AB, MB, ON)	137	133	97.1

Clinical Use and Value of SSR data

Thyroid Cancer

The proportion of patients who waited > 90 days for a surgical treatment

Indicator: Percent of patients waited >90 days for surgery, from the date the decision to treat was made to the date of surgery

Province	Total patients who underwent thyroid surgery	Number of patients who waited > 90 days for surgery	Percent (%)
<i>Provinces combined</i>	305	88	28.9

Opportunities: Expand SSR Adoption

- Leverage leading practices and clinical leaders across the country via a “network approach”
- Pan-Canadian endorsement—surgical synoptic reporting tools and indicators
- Governance
 - Content, informatics and technical standards
 - Implementation, change management and capacity building
- Provincial priorities and funding support:
 - IT infrastructure and support
 - Communication and education to manage change



Summary

Users of the surgical synoptic reports reported...

- Positive clinical impact—improved quality
 - increased awareness of relevant guidelines, safety, quicker access to reports by health care teams
 - Results in better surgical care and is cost effective
 - Identified treatments that have better outcomes
 - Improved ability to analyze outcomes and compare nationally

Future Direction –Build on the Success

The Partnership is working with a number of jurisdictions and clinicians:

- Measure a priority set of clinical indicators to further demonstrate the value of electronic synoptic surgical reporting
- Endorsement and adoption strategy for standards, indicators and reporting

Questions?



Visit us

<http://stg.cancerview.ca/cv/portal/Home/TreatmentAndSupport/TSPProfessionals/TSDiagnosisTreatment/SynopticReportingMS/SRSurgery?lang=en>



Email us surgery@partnershipagainstcancer.ca